Developer/Manufacturer
Developed by COMPANY
Sold under the brand name Revlimid.
Initial Registration
FDA
Application: BLA/NDA number
Approval: DATE
Initial indication:
Orphan status: Designation for
European Medicines Agency
Approval:
Orphan status:
Pre-Clinical Development
Principal Investigators for NIH grants/Inventors/Primaries
Public/Charity Funding of Revlimid
Licensing History of Revlimid
Narrative outlining brief history of licensing of Revlimid
[Link to IP Payment Timeline if available]
Clinical Trials Undertaken Before Approval
List/Table of Clinical Trials
Estimated out-of-pocket-costs for trials, before tax credits:
Estimate value of US ODTC:
Estimated value of US R&D tax credit:
Estimated cost of failures: before tax credits and deductions
Total Estimated Cost of Clinical Trials:
Total Estimated Cost of Clinical Trials, adjusted for risk and cost of capital: